Abstract

INTRAVENOUS MINOCYCLINE FOR TREATMENT OF MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII INFECTIONS

Dr. Vijay Kumar Mishra* and Dr. Arpan Dutta Roy

Abstract

A baumannii is intrinsically multidrug resistant. Only few antibiotics are active against this organism. Among Acinetobacter species, A. baumannii and other closely related species are commonly implicated in nosocomial infections. These organisms are usually multidrug resistant and therapeutic options to treat A. baumannii infections are very limited An intravenous formulation of minocycline has recently available for clinical use. Intravenous minocycline has high activity against Acinetobacter species .U.S. Food and Drug Administration (FDA) has also approved a supplemental new drug application for a new formulation of MINOCIN® (minocycline) for Injection and indicated for the treatment of infections due Acinetobacter species bacteria. Minocycline is an old drug that has the potential to become a important part of armamentarium against emerging infection such as CA-MRSA and A. Bumannii.

Keywords: Minocycline, Minocycline Combination therapy, intravenous, Acinetobacter baumannii.